NKp46‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats

Herein, we describe the generation of potent NK cell engagers (NKCEs) based on single domain antibodies (sdAbs) specific for NKp46 harboring the humanized Fab version of Cetuximab for tumor targeting. After immunization of camelids, a plethora of different VHH domains were retrieved by yeast surface display. Upon reformatting into Fc effector‐silenced NKCEs targeting NKp46 and EGFR in a strictly monovalent fashion, the resulting bispecific antibodies elicited potent NK cell‐mediated killing of EGFR‐overexpressing tumor cells with potencies (EC50killing) in the picomolar range. This was further augmented via co‐engagement of Fcγ receptor IIIa (FcγRIIIa). Importantly, NKp46‐specific sdAbs enabled the construction of various NKCE formats with different geometries and valencies which displayed favorable biophysical and biochemical properties without further optimization. By this means, killing capacities were further improved significantly. Hence, NKp46‐specific sdAbs are versatile building blocks for the construction of different NKCE formats.

[1]  M. Vetizou,et al.  Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant , 2022, Cell reports. Medicine.

[2]  S. Krah,et al.  Multifunctional NK Cell–Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release , 2022, The Journal of Immunology.

[3]  A. Rajpal,et al.  Designing antibodies as therapeutics , 2022, Cell.

[4]  M. Peipp,et al.  Immunotherapeutic Targeting of Activating Natural Killer Cell Receptors and their Ligands in Cancer. , 2022, Clinical and experimental immunology.

[5]  É. Vivier,et al.  Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia , 2022, Cancer immunology research.

[6]  A. Evers,et al.  Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities , 2022, mAbs.

[7]  H. Kolmar,et al.  Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection , 2022, Frontiers in Immunology.

[8]  G. Curigliano,et al.  Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 , 2021, Journal for ImmunoTherapy of Cancer.

[9]  M. Chiron,et al.  852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC , 2021, Journal for ImmunoTherapy of Cancer.

[10]  David Killock.  Tebentafusp for uveal melanoma , 2021, Nature Reviews Clinical Oncology.

[11]  Sandeep Kumar,et al.  Intrinsic physicochemical profile of marketed antibody-based biotherapeutics , 2021, Proceedings of the National Academy of Sciences.

[12]  O. Demaria,et al.  Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments , 2021, European journal of immunology.

[13]  S. Krah,et al.  Antibody display technologies: selecting the cream of the crop , 2021, Biological chemistry.

[14]  J. Koch,et al.  Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors , 2021, mAbs.

[15]  Wei Chen,et al.  One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics , 2021, mAbs.

[16]  L. Sehn,et al.  Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial , 2020 .

[17]  Joseph Cursons,et al.  The cancer–natural killer cell immunity cycle , 2020, Nature Reviews Cancer.

[18]  Michael Hust,et al.  A One-Step Process for the Construction of Phage Display scFv and VHH Libraries , 2020, Molecular Biotechnology.

[19]  M. Busch,et al.  Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform , 2020, mAbs.

[20]  M. Busch,et al.  Isolation of Antigen-Specific VHH Single-Domain Antibodies by Combining Animal Immunization with Yeast Surface Display. , 2020, Methods in molecular biology.

[21]  Yongping Song,et al.  Recent advances on blinatumomab for acute lymphoblastic leukemia , 2019, Experimental Hematology & Oncology.

[22]  M. Carlsten,et al.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells , 2019, Front. Immunol..

[23]  S. González,et al.  NK Cells in the Treatment of Hematological Malignancies , 2019, Journal of clinical medicine.

[24]  P. Parren,et al.  Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.

[25]  A. Roussel,et al.  Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity , 2019, Cell.

[26]  Weilei Hu,et al.  Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities , 2019, Front. Immunol..

[27]  P. Chames,et al.  Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer , 2019, Antibodies.

[28]  Stanley R Krystek,et al.  AggScore: Prediction of aggregation‐prone regions in proteins based on the distribution of surface patches , 2018, Proteins.

[29]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[30]  H. Kolmar,et al.  Engineering IgG-Like Bispecific Antibodies—An Overview , 2018, Antibodies.

[31]  B. Brors,et al.  Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential , 2018, Proceedings of the National Academy of Sciences.

[32]  H. Kolmar,et al.  Engineering bispecific antibodies with defined chain pairing. , 2017, New biotechnology.

[33]  Fenghua Wang,et al.  FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer , 2017, OncoTargets and therapy.

[34]  J. Koch,et al.  Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy , 2017, Transfusion Medicine and Hemotherapy.

[35]  Harald Kolmar,et al.  Camelid and shark single domain antibodies: structural features and therapeutic potential. , 2017, Current opinion in structural biology.

[36]  Andrew D. Tustian,et al.  Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity , 2016, mAbs.

[37]  Harald Kolmar,et al.  Single-domain antibodies for biomedical applications , 2016, Immunopharmacology and immunotoxicology.

[38]  R. Sun,et al.  Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack , 2014, The Journal of Biological Chemistry.

[39]  S. Lohse,et al.  Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity , 2014, mAbs.

[40]  S. Muyldermans,et al.  A general protocol for the generation of Nanobodies for structural biology , 2014, Nature Protocols.

[41]  P. Altevogt,et al.  Microenvironment and Immunology Metalloprotease-Mediated Tumor Cell Shedding of B 7-H 6 , the Ligand of the Natural Killer Cell – Activating Receptor NKp 30 , 2014 .

[42]  M. Hallek,et al.  Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. , 2013, Blood.

[43]  P. Lang,et al.  Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies , 2013, Front. Immunol..

[44]  Sven Berger,et al.  Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies , 2012, The Journal of Immunology.

[45]  P. Queirolo,et al.  Melanoma cells become resistant to NK‐cell‐mediated killing when exposed to NK‐cell numbers compatible with NK‐cell infiltration in the tumor , 2012, European journal of immunology.

[46]  R. Solana,et al.  NK Cell Recognition and Killing of Melanoma Cells Is Controlled by Multiple Activating Receptor-Ligand Interactions , 2011, Journal of Innate Immunity.

[47]  J. Huston,et al.  SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.

[48]  M. Ychou,et al.  Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  L. Ciuffreda,et al.  Journal of Translational Medicine BioMed Central Commentary Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines , 2004 .

[50]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[51]  A. Wolf,et al.  High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. , 2006, Molecular immunology.

[52]  M. Hallek,et al.  A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. , 2006, Blood.

[53]  Y. Durocher,et al.  High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. , 2002, Nucleic acids research.

[54]  R. Biassoni,et al.  Identification and Molecular Characterization of NKp 30 , a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells , 1999 .

[55]  M. Fanger,et al.  Bispecific antibodies. , 1992, Critical reviews in immunology.

[56]  I. Kimber.  Natural killer cells. , 1985, Medical laboratory sciences.